Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer

杜瓦卢马布 医学 放化疗 传统PCI 危险系数 内科学 预防性头颅照射 化学免疫疗法 肺癌 放射治疗 肿瘤科 外科 化疗 置信区间 癌症 无容量 环磷酰胺 免疫疗法 心肌梗塞
作者
Sehhoon Park,Jae Myoung Noh,Yoon‐La Choi,Sang Ah,Kyunga Kim,Hyun Ae Jung,Se‐Hoon Lee,Jin Seok Ahn,Myung‐Ju Ahn,Jong‐Mu Sun
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:169: 42-53 被引量:26
标识
DOI:10.1016/j.ejca.2022.03.034
摘要

The current standard treatment for limited-stage small-cell lung cancer (LS-SCLC) is chemotherapy with concurrent chemoradiotherapy (CCRT).In this single-arm phase II study, patients with LS-SCLC received four cycles of etoposide, cisplatin, and durvalumab every 3 weeks. Thoracic radiotherapy of 52.5 Gy in 25 once-daily fractions was started with the third cycle of chemoimmunotherapy. After CCRT plus durvalumab, patients received durvalumab consolidation therapy every 4 weeks for a maximum of 2 years after study enrolment. Prophylactic cranial irradiation (PCI) was recommended.Fifty-one patients were enrolled, and 50 were included in the full analysis set. With the median follow-up duration of 26.6 months, the median PFS was 14.4 months (95% confidence interval: 10.3-NA), and the 24-month PFS rate was 42.0%. The median overall survival was not reached with a 24-month overall survival rate of 67.8%. The positive PD-L1 group (n = 22) was not associated with longer PFS (hazard ratio, 0.70; 0.31-1.58) and overall survival (0.64; 0.22-1.84) compared with the negative PD-L1 group (n = 20). Among the 43 patients who were candidates for PCI treatment, the PCI group (n = 22) had significantly fewer events of brain metastasis as the first failure sites compared to the no PCI group (n = 21) (13.6% vs. 42.9%, P = 0.033). There were several grade 3 or 4 adverse events which were well managed with appropriate supportive care.Durvalumab with CCRT for LS-SCLC exhibited promising clinical efficacy with a tolerable safety profile, prompting its validation in a randomized study.NCT03585998.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
3秒前
4秒前
开放觅夏完成签到,获得积分10
4秒前
热情凝云完成签到,获得积分10
7秒前
探寻发布了新的文献求助10
7秒前
甘博发布了新的文献求助10
7秒前
我是老大应助AURORA98采纳,获得10
8秒前
飘逸小懒猪应助AURORA98采纳,获得50
8秒前
所所应助AURORA98采纳,获得10
8秒前
jyy应助AURORA98采纳,获得50
8秒前
8秒前
xinxin发布了新的文献求助10
11秒前
11秒前
12秒前
小鱼完成签到,获得积分20
13秒前
13秒前
CodeCraft应助sbw采纳,获得10
14秒前
零一发布了新的文献求助10
18秒前
xinxin完成签到,获得积分10
18秒前
桑叶发布了新的文献求助10
18秒前
量子星尘发布了新的文献求助10
18秒前
傲娇衬衫发布了新的文献求助10
19秒前
Hello应助友好驳采纳,获得10
21秒前
阿桂发布了新的文献求助10
22秒前
23秒前
24秒前
Longfenzhong完成签到,获得积分10
24秒前
零一完成签到,获得积分10
24秒前
breaddog完成签到,获得积分10
25秒前
思源应助实验顺顺利利采纳,获得10
26秒前
迅速孤容完成签到 ,获得积分10
27秒前
27秒前
桑叶完成签到 ,获得积分10
27秒前
27秒前
GGKing完成签到,获得积分10
29秒前
研友_VZG7GZ应助傲娇衬衫采纳,获得10
30秒前
GGKing发布了新的文献求助10
31秒前
冰释发布了新的文献求助30
31秒前
wade发布了新的文献求助10
32秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975755
求助须知:如何正确求助?哪些是违规求助? 3520108
关于积分的说明 11200829
捐赠科研通 3256492
什么是DOI,文献DOI怎么找? 1798298
邀请新用户注册赠送积分活动 877509
科研通“疑难数据库(出版商)”最低求助积分说明 806403